EP2767537A1 — Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Assigned to Medivation Technologies LLC · Expires 2014-08-20 · 12y expired
What this patent protects
The invention provides a compound of the formula: or a pharmaceutically acceptable salt or solvate thereof. Also provided are pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carr…
USPTO Abstract
The invention provides a compound of the formula: or a pharmaceutically acceptable salt or solvate thereof. Also provided are pharmaceutical compositions comprising the compound or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient, binder or diluent. The compounds and compositions of the invention are useful for the treatment of cancer.
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.